KALA BIO, Inc. — Director's Dealing 2017

Jul 27, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-25

Reporting Person: Longitude Capital Partners II, LLC (10% Owner)
Reporting Person: ENRIGHT PATRICK G (10% Owner)
Reporting Person: Tammenoms Bakker Juliet (10% Owner)
Reporting Person: Longitude Venture Partners II, L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-07-25	Common Stock	C	2055946	—	Acquired	2055946	Indirect
2017-07-25	Common Stock	P	215000	$15.00	Acquired	2270946	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-25	Series C Preferred Stock	$	C	10707985	Disposed		Common Stock (2055946)	Indirect

Footnotes

F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.